Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Price comparisons should account for purity differences and testing standards
Looking Ahead GLP-1 drugs have revolutionized treatment for obesity, but recent regulatory activity is a reminder that existing rules apply even when the innovation is revolutionary
Other federal agencies, including the Social Security Administration, the National Institutes of Health and the IRS, already consider obesity a disease, while the Department of Defense and the Department of Veterans Affairs provide coverage for anti-obesity medications
Clinical trial data on weight regain The STEP-10 extension trial revealed that participants who stopped semaglutide regained over 40% of their lost weight within just 28 weeks
